Final answer:
Acute Lymphoblastic Leukemia (ALL) is the most common type of cancer in children, classified by the type of lymphocytes affected, with B-cell ALL and T-cell ALL as common subtypes. Markers such as CD10, CD19, CD20 for B-cell ALL, and CD2 to CD8 for T-cell ALL are essential for diagnosis and treatment. Research continues to advance treatments and potential cures for ALL.
Step-by-step explanation:
Acute Lymphoblastic Leukemia (ALL) - Pediatric MalignancyAcute Lymphoblastic Leukemia (ALL) is the most common pediatric malignancy, affecting a significant portion o children with cancer. In ALL, abnormal white blood cells are produced in the bone marrow, leading to symptoms like fatigue, infections, and easy bruising. ALL can be classified into subtypes based on the lymphocytes affected; B-cell ALL and T-cell ALL being the most commonly identified types. Markers and Subtypes of ALLMarkers, or specific proteins on the surface of cells, help classify ALL subtypes. For instance, B-cell ALL may present with CD10, CD19, and CD20 as markers, while T-cell ALL might show CD2 to CD8. Understanding these markers is crucial for diagnosis and treatment planning. It is important to note that leukemia, particularly ALL, constitutes a third of all childhood cancers, highlighting the significance of recognizing its markers and subtypes to provide targeted treatment options. Research, like those funded by fundraising events, is essential in the development of medical advancements to treat and potentially cure leukemia.